Bispecific antibody therapy for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies new treatments called bispecific antibodies for multiple myeloma, a type of blood cancer. These therapies aim to help patients who have had their disease come back after other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma.
- You are being considered for a bispecific antibody, CAR-T, or other myeloma treatment.
- You are able to give informed consent, meaning you understand the study and agree to participate.
- You are able to have a bone marrow sample taken.
- You are not pregnant.
- You are 18 years or older and not legally incapacitated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs for people newly diagnosed with a high-risk form of multiple myeloma. The goal is to see if this combination is safe and works better than standard treatments.
This study tests two drugs together to see if they can help people with multiple myeloma that has come back after other treatments. It aims to shrink or control the cancer and may offer a new option for patients who have already tried several therapies.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This study tests a two-step approach for people with relapsed or hard-to-treat multiple myeloma. First, you get a bispecific antibody (a drug that helps your immune system attack myeloma cells), then you receive CAR-T cell therapy (your own immune cells modified to fight the cancer). The goal is to see if this combination works well together.
This trial tests a type of immune therapy called bispecific T-cell redirectors combined with standard medicines for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if this treatment helps control the cancer better.
This trial tests a new drug called a bispecific antibody (which helps your immune system attack myeloma cells) as a 'bridge' treatment before you receive CAR-T cell therapy. The goal is to control the disease better and improve the success of the CAR-T treatment.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.